Background-Extracorporeal membrane oxygenation (ECMO) provides circulatory and respiratory support for patients with severe acute cardiopulmonary failure. The objective of this study was to examine the survival outcomes for patients who received ECMO. Methods and Results-Adult patients who received ECMO from September 1, 2002, to December 31, 2012 from the Taiwan National Health Insurance Database associated with coronary artery bypass graft surgery, myocardial infarction/cardiogenic shock, injury, and infection/septic shock. A Cox regression model was used to determine hazard ratios and to compare 30-day and 1-year survival rates with the myocardial infarction/cardiogenic shock group used as the reference. The mean±SD age of the 4227-patient cohort was 57±17 years, and 72% were male. The overall mortalities were 59.8% and 76.5% at 1 month and 1 year. Survival statistics deteriorated sharply when ECMO was required for >3 days. Acute (30-day) survival was more favorable in the infection/septic shock (n=1076; hazard ratio, 0.61; 95% confidence interval, 0.55-0.67), coronary artery bypass graft surgery (n=1077; hazard ratio, 0.68; 95% confidence interval, 0.61-0.75), and injury (n=369, hazard ratio, 0.82; 95% confidence interval, 0.70-0.95) groups. The extended survival rapidly approached an asymptote near 20% for the infection/septic shock, myocardial infarction/cardiogenic shock (n=1705), and coronary artery bypass graft surgery groups. The pattern of survival for the injury group was somewhat better, exceeding 30% at year-end. Conclusions-Regardless of initial pathology, patients requiring ECMO were critically ill with similar guarded prognoses.
E xtracorporeal membrane oxygenation (ECMO) provides circulatory and respiratory support and allows the extended survival of select patients with severe acute cardiopulmonary failure refractory to conventional treatment. 1 ECMO was initially introduced in the 1970s to assist neonates with severe respiratory failure. 2 Since then, its indications have been gradually expanded into different aspects of resuscitation medicine. [3] [4] [5] In patients waiting for heart or lung transplantation, ECMO helps to preserve associated tissue function and to forestall irreversible changes in other major organs. [6] [7] [8] ECMO is indicated for similar reasons in patients with severe cardiopulmonary compromise secondary to accidental and surgical trauma 9 and seems to improve outcomes for cardiopulmonary resuscitation after cardiac arrests occurring both in and out of the hospital. [10] [11] [12] As a result of many "miraculous" experiences, intensive care facilities everywhere in Taiwan are adopting ECMO technology. 13, 14 The Taiwan National Health Insurance (NHI) initiated reimbursement for the high costs of ECMO therapy in 2002, further supporting its rapidly expanding implementation in the years since. The criteria for instituting ECMO in adult patients included cardiogenic shock of various origins, respiratory failure (defined as Pao 2 <60 mm Hg under 100% Fio 2 , CO 2 retention, or a bridge to lung transplantation) resulting from infectious or noninfectious processes, airway injury, and hypothermia (core temperature ≤30°C). 15 ECMO is most used as a last resort for patients with severe refractory shock. The Taiwan NHI claims database contains extensive clinical data obtained during the roll out of this therapeutic modality and thus allows the study of the outcomes of patients on ECMO.
Despite the efficacy of prompt ECMO support as an acute lifesaving strategy in cardiovascular emergencies, the overall mortality associated with cardiogenic shock is still high. 16 Moreover, there is currently little recorded evidence supporting ECMO use in severe trauma and sepsis. 17, 18 Therefore, this study was designed to quantify survival outcomes for adult patients who received ECMO for the most common medical indications recorded during the interval of 2002 to 2012 and to identify the risk factors associated with short-and long-term mortality.
Methods

Data Source
A universal compulsory national health insurance program was launched by the Taiwanese government in March 1995. The Taiwan NHI database includes complete outpatient visits, hospital admissions, prescriptions, diseases, and vital status for 99% of the country's population (≈23 million) in Taiwan. Several computerized claims data sets were linked with the National Death Registry through the use of birth dates and civil identification numbers unique to each beneficiary. The protocol of this study was approved by the National Taiwan University Hospital Research Ethics Committee.
Study Population
Data for all patients with health insurance reimbursement codes of extracorporeal life support in the inpatient claims database between December 1, 2002 , and December 31, 2012, were retrieved. Services and procedure codes used to identify patients who received ECMO are listed in Table I in the online-only Data Supplement. The date of hospitalization was defined as the index date. For those who had ≥2 hospitalizations for the procedure, the date of the first hospitalization was defined as the index date. The study included only adults ≥20 years of age. Organ donors, cancer patients, and women with obstetric labor complications were also excluded because their unique baseline characteristics and prognoses made it difficult to assign them to the defined major categories.
Comparison Groups and Outcome Definition
The patients were classified into 4 major comparison groups of ECMO associated with coronary artery bypass graft surgery (CABG), myocardial infarction (MI)/cardiogenic shock (CS), injury (including fractures, trauma, and poisoning), and infection/septic shock (infection). Patients coded as hospitalized for major cardiac surgery were assigned to the CABG group if they also had coding for both ECMO and CABG. ECMO coding associated with other surgical procedures and potentially mistaken coding of cardiopulmonary bypass in operations were filtered out. Patients hospitalized for MI or CS during the index hospitalization for ECMO were assigned to the second group (MI/CS) on the basis of International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes ( Table I in the  online-only Data Supplement) . Similarly, ICD-9-CM codes were used to identify ECMO patients in the injury and infection groups ( Table I in the online-only Data Supplement). Adult patients receiving ECMO who were not categorized into 1 of these 4 primary groups were thus excluded. A preliminary validation analysis determined that this algorithm successfully allocated the patients to the 4 study groups with an accuracy exceeding 97%. The primary target outcome of death was ascertained by linking patient identifications to the National Death Registry.
Covariate Ascertainment
Inpatient and outpatient diagnosis and prescription files during the 12 months before the index date were used to ascertain patients' history of comorbidities such as diabetes mellitus, hypertension, heart disease, stroke, and a variety of conditions (ICD-9-CM codes listed in Table I in the online-only Data Supplement). The anatomic therapeutic chemical codes ( Table I in the online-only Data Supplement) for resuscitation medications, including dopamine, norepinephrine, bicarbonate, vasopressin, atropine, and epinephrine, at the index hospitalization were summarized. Other demographic data, including age, sex, monthly income level as a proxy of socioeconomic status, and resource use (number of outpatient visits, number of emergency room visits, number of hospitalizations, and average days of hospitalizations) during the 12 months before the index date, were collected. Complications such as ischemic stroke, limb ischemia, intracranial hemorrhage, gastrointestinal hemorrhage, and acute renal failure were estimated from the diagnostic codes during hospitalization.
Statistical Analysis
Baseline characteristics, comorbidities, and resource use for the 4 primary groups receiving ECMO in 2002 to 2012 were summarized. Hospital mortality, 30-day mortality, 1-year mortality, ECMO days, and hospitalization days for each diagnostic group were reported. The percentage of patients remaining on ECMO and the cumulative survival were plotted over the number of ECMO days.
In the NHI claims database, the exact date of ECMO institution could not be ascertained. In most cases, it should be the same as or very close to (within 1 or 2 days) the index date. The counting of survival time in days started from the index date until 1 year, death, or study termination (December 31, 2012) . Kaplan-Meier curves were constructed for the 4 comparison groups to illustrate the survival patterns during the year after treatment. Because 30-day mortality has long served as a traditional yardstick for surgical quality, 19 detailed risk analyses were determined at 30 and 365 days. Survival curves also seemed to cross over at ≈30 days.
Cox proportional hazards regression models were used to calculate the hazard ratios (HRs) and their 95% confidence intervals (CIs) in the early (within 30 days) and later (31-365 days) follow-up periods. The MI/CS group was designated the reference group for the survival benefit analysis because it was the largest group with potentially the poorest prognosis. The analyses were adjusted for sex, age, Charlson Comorbidity Index, 20, 21 and hospital level (medical center or not). Because survival curves might not follow the proportional hazards assumption, an additional time-varying survival analysis was performed for the 365-day follow-up period. In this regard, an interaction term was added between the ECMO group and time to model the potential that the between-group survival trends might differ before and after day 30. All statistical analyses were performed with SAS 9.2 (SAS Institute, Cary, NC).
Subgroup Analyses
The study examined outcomes in patients over a 10-year period that included the time when ECMO reimbursement was introduced, disseminated, and widely used in the healthcare system. The procedure code for ECMO was changed on September 1, 2009. A subgroup analysis was performed to explore the outcomes of the patients in the periods before and after that date.
In addition, CABG patients were further analyzed as 2 subgroups, those who underwent ECMO after cardiac surgery (CABG-ECMO) and those who were pretreated with ECMO before cardiac surgery (ECMO-CABG). The baseline characteristics, follow-up, and mortality patterns were reported as described above. underwent cardiac surgical procedures, and the remaining 3322 received ECMO for other reasons. The cardiac surgery cohort included 1077 patients who were assigned to the CABG group ( Figure 1 ). The remaining 2867 cardiac surgical patients received only cardiopulmonary bypass during surgery and had a spectrum of procedures with insufficient numbers for further analysis ( Table I in the online-only Data Supplement). The other 3322 patients who did not receive any cardiac surgery were assigned to groups as follows: MI/CS, n=1705; injury, n=369; infection, n=1076; and others, n=172. In summary, a total of 4227 subjects were assigned to the CABG, MI/CS, injury, and infection groups for analysis (all patients in Figure 1 ). The mean±SD age of the 4227 patient cohort was 57±17 years, and 72% were male.
The main diagnoses for the index hospitalizations among the 4 groups combined were acute MI (ICD-9-CM code 410.x; n=1072); other forms of chronic ischemic heart disease (ICD-9-CM code 414.x; n=439); pulmonary insufficiency after trauma and surgery (ICD-9-CM code 518.x; n=207); pneumonia, organism unspecified; heart failure; acute myocarditis; CS; cardiac arrest; influenza; and pulmonary embolism/ infarction ( Table II in the online-only Data Supplement). The patients in the 4 comparison groups differed substantially with respect to main diagnoses ( Table II in the online-only Data Supplement) and baseline characteristics ( Table 1) . The patients in the injury group were younger, had fewer comorbidities, and used fewer healthcare services before the index hospitalization. In contrast, the patients in the CABG and the MI/CS groups were more likely to have diabetes mellitus, hypertension, and cardiovascular disease with a higher Charlson Comorbidity Index. Not unexpectedly, the CABG and MI/CS groups shared a similar spectrum of atherosclerotic cardiovascular disease (Table II in the online-only Data  Supplement) , differing with respect to the inclusion of CABG in the therapeutic course. Those in the infection group were more likely to have a history of chronic liver and lung disease. This chronic disease profile was associated with a greater use of medical resources as indicated by more outpatient visits, emergency room visits, and hospitalizations during the year before the index day ( Table 1) . The most frequent complications associated with ECMO use were acute renal failure (21.3%), followed by major bleeding events (gastrointestinal bleeding, 3.1%; intracranial bleeding, 1.7%) and ischemic stroke (3.1%), among all patients. Acute renal failure was also the foremost complication in the 4 primary groups (Table III in the online-only Data Supplement).
Patients selected for EMCO support are generally among the most seriously ill. As a result, the mean follow-up for the 4227 patients assigned to the 4 comparison groups was only 98 days. The average duration of ECMO support was 2.14 days. The overall mortality was 30.1%, 59.8%, and 76.5% at days 7, 30, and 365, respectively. The hospital discharge Table 2 . The number of days on ECMO was associated with a negative prognosis. Only a small percentage of patients used ECMO for >3 days (Figure 2A ), and positive survival outcomes became less likely as the duration of ECMO increased ( Figure 2B ). The Kaplan-Meier curves illustrates that, in the first 30 days, the patients in the infection group fared best and survival in the MI/CS group was poorest ( Figure 3A ). With MI/ CS used as the reference, the adjusted HRs and confidence limits at 1 month were 0.61 (95% CI, 0.55-0.67) for the infection group, 0.68 (95% CI, 0.61-0.75) for the CABG group, and 0.82 (95% CI, 0.70-0.95) for the injury group (Table 3) . Additional Kaplan-Meier curves were plotted for the subsequent 31-to 365-day period ( Figure 3B ) for patients who survived the first 30 days. The adjusted HRs were 0.98 (95% CI, 0.68-1.41) for the injury group, 1.31 (95% CI, 1.07-1.60) for the CABG group, and 2.00 (95% CI, 1.66-2.42) for the infection group (Table 3) for this second follow-up interval.
When the follow-up was combined for the full 0-to 365-day period, the patients in the injury group had the highest survival and the patients in the CABG, MI/CS, and infection groups all displayed similarly lower survival probability of ≈20% ( Figure   3C ). Because the 365-day survival curves did not seem proportional to each other, the group-time interaction showed that the HRs changed after day 30 and that the hazards increased in the CABG group (interaction HR, 2.28; 95% CI, 1.83-2.84) and infection group (interaction HR, 3.28; 95 CI, 1.83-2.84) but not in the injury group (interaction HR, 0.88; 95% CI, 0.60-1.30; Table IV in the online-only Data Supplement).
The subgroup analysis based on the inclusion date before and after September 1, 2009, showed that there were no major differences in outcomes except that the death rate was lower in the infection group in the latter period (Table V in the onlineonly Data Supplement).
The CABG group was further divided into 486 patients receiving ECMO after CABG (CABG-ECMO) and the other 591 patients receiving ECMO before CABG (ECMO-CABG). The analysis showed that the 7-day, 30-day, and 1-year death rates were 20.2%, 57.2%, and 77.2% in the CABG-ECMO subgroup and 25.6%, 60.6%, and 80.7% in the ECMO-CABG subgroup. The hospital discharge rates were 37.2% and 33.8%, respectively ( Table VI in 
Discussion
This analysis of the nationwide cohort demonstrated that the hospital discharge rate was 35% and the overall 1-year survival of patients receiving ECMO was 24%. Patients with severe infection or septic shock might have better outcomes Strengths of the study arise from the large number of subjects (>4000) and decade-long duration, making it one of the largest ECMO cohorts evaluated. With the unique coding system and a linkage to the Taiwan National Death Registry, survival characteristics associated with ECMO could be ascertained. Bias associated with delays in reporting represented far less than 1% of the overall mortality in the data set analyzed. There was more than sufficient time to collect data so that the effect of any delays in reporting would have been minimal even for the last 2 years of the study period. The 
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results of this analysis indicate that the outcomes are related to the initial indication, that is, the original cause that necessitates the life support. 22 Acute coronary syndrome complicated by shock is associated with high mortality despite the use of percutaneous support devices. 23, 24 Previously reported discharge rates in selected small case studies were ≈30 to 40%. 25, 26 In this series, coronary patients requiring ECMO had discharge rates of 35% regardless of whether CABG was performed. Despite better results in the CABG group at 30 days, both the CABG and MI/CS patients had similarly poor long-term survival rates. Patients who required ECMO before cardiac surgery (ECMO-CABG) may represent a more seriously ill population than those deemed sufficiently stable to go directly to surgery. On the other hand, those requiring postsurgical ECMO (CABG-ECMO) may represent those with the poorest postsurgical prognosis. Although the differences were not great, the discharge rate and survival statistics were better among those stable enough to elect surgery without prior ECMO support. The application of ECMO to preserve organ function when the lungs are compromised as a result of injury is a logical premise, and a few recent reports have suggested that ECMO is helpful in severely injured patients. 17 Only a few small series have argued that ECMO support could improve outcome in patients with disastrous trauma with coexisting chest injury or bleeding shock. 9, 27, 28 The preservation of major organ function by ECMO may indeed provide a better chance for survival in these patients. The present study showed a better outcome in this group of patients, especially when they survived the first month.
Sepsis-related acute respiratory distress syndrome has a higher overall disease severity. ECMO has been used as a rescue therapy for the most severe form of acute respiratory distress syndrome. The findings from the Conventional Ventilation or Extracorporeal Membrane Oxygenation for Severe Adult Respiratory Failure (CESAR) trial showed that ECMO increases survival among adult patients with severe but potentially reversible respiratory failure compared with conventional ventilatory support. 29, 30 However, experience with ECMO for adult patients with refractory septic shock is still limited, and the outcomes remain unsatisfactory. 31 A previous study of 52 patients showed that most septic patients developed multiple organ failure and only 15% survived to hospital discharge. 18 In the present series analysis, about half the ECMO-treated septic patients survived the first month after ECMO support, but the overall mortality at the end of 1 year was still very high. The application of ECMO in septic patients presumably helps to maintain homeostasis among proinflammatory and anti-inflammatory mediators and to reduce intravascular coagulation. 32 Although the rationale and mechanistic basis for using ECMO in sepsis are logical, the value of ECMO remains under debate. 33 A variety of experimental techniques such as absorption hemofiltration, blood purification, and immunomodulation alone and in combination with ECMO may shed new light on its value in septic shock treatment. 34, 35 Acute renal failure was the most frequent complication in our series. Acute kidney injury that developed during ECMO could be attributed to multiple factors such as sepsis, low cardiac output syndrome, exposure to nephrotoxic agents, and high intrathoracic pressures. 36 Previous studies have shown that the mortality associated with acute kidney injury was still high 37 and that the prognosis was related to age, acute physiology, and chronic health status. 38 Therefore, it is necessary to screen for acute kidney injury throughout the time course to improve outcomes in this at-risk adult population. Finally, renal failure and the other major complications (gastrointestinal bleeding, intracranial bleeding and ischemic stroke) may all have intravascular origins in common. 39 Thus, the circulating hematologic, humoral, and inflammatory status of these patients should be aggressively monitored and optimized. 40 Taiwan's NHI is the single payer for reimbursing the applications of ECMO. The rules suggest that that ECMO should be reserved to the hospitals equipped with a qualified cardiovascular program that includes appropriate critical care specialties. There is no absolute restriction in the number of ECMO circuits or days of maintenance. However, practical experience suggests that claims for ECMO reimbursement exceeding 1 week are reviewed carefully and may be declined. Inappropriate or extended application surely occurs on occasion in an effort to do everything possible and as a result of the natural reluctance to withdraw any life-supporting technology. Thus, there is an emerging concern that ECMO could be overused in Taiwan because clinical indications are broad. 41 ECMO is applied only in very critical conditions when patients are expected to die without the intervention. The concern of overuse implies that ECMO is a futile exercise in a subset of patients who are not likely to benefit from its institution. 42 The present analysis suggests that 20% in each group survived through year-end. The challenge thus resides in determining objective criteria to identify who will and will not benefit. Until that time, the interval between discharge and 1 year provides an important window of opportunity to dissect the secondary mortality risk and to institute logical adjunct adjustments.
A recent study reported that the median expenditure of ECMO was approximately US $20 000 per case in Taiwan, 41 a number far lower than that reported in the United Kingdom (ie, $108 000). 30 Because the monetary figures are difficult to compare across health systems and economies, the costs of related procedures may be helpful. For example, the average expenditure in Taiwan was US $5500 for coronary bypass surgery, 43 $6400 for radiofrequency catheter ablation for atrial fibrillation, 44 $10 000 for bare metal stent implantation, and $11 700 for drug-eluting stent implantation in the treatment of stable coronary artery disease. 45 Unlike these other elective procedures, ECMO is generally reserved for those with the lowest chances of immediate survival. The institution of government reimbursement for ECMO in Taiwan and its expanded use must have resulted in a substantial financial burden but also must have provided an economy of scale. Like all other evolving therapies, its cost-effectiveness should be carefully and continuously evaluated.
There are several limitations in this study. First, crucial information on vital signs and titration of inotropic agents was not available, and thus, the hemodynamic status before and after ECMO institution was unknown. 
Conclusions
ECMO as increasingly applied in Taiwan has provided long-term survival outcomes comparable to those reported in previous studies. The prognosis for patients with MI and CS was poor regardless of whether CABG was performed. On the other hand, patients with severe trauma had a better long-term outcome. Infection and septic shock were associated with better initial outcomes, which deteriorated over time, suggesting again the need to use this early window of opportunity to aggressively study these patients. Initial pathogenesis and indications largely affected the outcomes of the patients receiving ECMO in Taiwan. Thus, the mechanisms of action may differ. Given the severely critical condition of most patients receiving ECMO, one must assume that the 35% discharge rate reported in this series represents an immediate success. However, further studies are warranted to examine the outcomes of these interventions, especially between discharge and death, and to evaluate the cost-effectiveness of this lifesaving technology for each indication.
CLINICAL PERSPECTIvE
Extracorporeal membrane oxygenation (ECMO) therapy for critically ill patients is clinically logical as an interim form of cardiopulmonary support and as an external adjuvant to preserve vulnerable ischemic organ systems. Assuming that ECMO is reserved largely for those expected to succumb shortly without this assistance, the subsequent 35% hospital discharge rate reported here might be considered a positive. One must note that comparable data without ECMO were not available in this study. However, the steep losses before discharge suggest that there is significant room for improvement in the application of ECMO protocols alone and in combination with other complementary therapies. The subsequent loss of another one third of patients during the year after their hospital discharge also suggests the need for aggressive monitoring of this cohort to identify the causes of these later fatalities and to develop strategies to prevent them. As one would expect, the analyses show that when the crisis arises from chronic illness in older populations, patients fare less well than their younger counterparts in whom the crisis more often results from acute traumatic injury. The increasing availability of ECMO systems and the wider reimbursement for their use in patients in Taiwan appear to have resulted in a significant reduction in comparable costs. Despite these positives, the application of new high-tech and often expensive methodologies requires constant re-evaluation of both efficacy and costs. Supplementary Table 1 . ICD-9-CM codes, ATC codes for resuscitation medications, and procedure/service codes for ECMO used in this study circulatory and respiratory support and allows the extended survival of select patients with severe acute cardiopulmonary failure refractory to conventional treatment. 1 ECMO was initially introduced in the 1970s to assist neonates with severe respiratory failure. 2 Since then, its indications have been gradually expanded into different aspects of resuscitation medicine. [3] [4] [5] In patients waiting for heart or lung transplantation, ECMO helps to preserve associated tissue function and to forestall irreversible changes in other major organs. [6] [7] [8] ECMO is indicated for similar reasons in patients with severe cardiopulmonary compromise secondary to accidental and surgical trauma 9 and seems to improve outcomes for cardiopulmonary resuscitation after cardiac arrests occurring both in and out of the hospital. [10] [11] [12] As a result of many "miraculous" experiences, intensive care facilities everywhere in Taiwan are adopting ECMO technology. 13, 14 The Taiwan National Health Insurance (NHI) initiated reimbursement for the high costs of ECMO therapy in 2002, further supporting its rapidly expanding implementation in the years since. The criteria for instituting ECMO in adult patients included cardiogenic shock of various origins, respiratory failure (defined as Pao 2 <60 mm Hg under 100% Fio 2 , CO 2 retention, or a bridge to lung transplantation) resulting from infectious or noninfectious processes, airway injury, and hypothermia (core temperature ≤30°C). 15 ECMO is most used as a last resort for patients with severe refractory shock. The Taiwan NHI Background-Extracorporeal membrane oxygenation (ECMO) provides circulatory and respiratory support for patients with severe acute cardiopulmonary failure. The objective of this study was to examine the survival outcomes for patients who received ECMO. claims database contains extensive clinical data obtained during the roll out of this therapeutic modality and thus allows the study of the outcomes of patients on ECMO. Despite the efficacy of prompt ECMO support as an acute lifesaving strategy in cardiovascular emergencies, the overall mortality associated with cardiogenic shock is still high. 16 Moreover, there is currently little recorded evidence supporting ECMO use in severe trauma and sepsis. 17, 18 Therefore, this study was designed to quantify survival outcomes for adult patients who received ECMO for the most common medical indications recorded during the interval of 2002 to 2012 and to identify the risk factors associated with short-and long-term mortality.
SUPPLEMENTAL MATERIAL
Methods and Results-Adult
Methods
Data Source
Study Population
Data for all patients with health insurance reimbursement codes of extracorporeal life support in the inpatient claims database between December 1, 2002, and December 31, 2012, were retrieved. Services and procedure codes used to identify patients who received ECMO are listed in Table I in the online-only Data Supplement. The date of hospitalization was defined as the index date. For those who had ≥2 hospitalizations for the procedure, the date of the first hospitalization was defined as the index date. The study included only adults ≥20 years of age. Organ donors, cancer patients, and women with obstetric labor complications were also excluded because their unique baseline characteristics and prognoses made it difficult to assign them to the defined major categories.
Comparison Groups and Outcome Definition
Covariate Ascertainment
Statistical Analysis
In the NHI claims database, the exact date of ECMO institution could not be ascertained. In most cases, it should be the same as or very close to (within 1 or 2 days) the index date. The counting of survival time in days started from the index date until 1 year, death, or study termination (December 31, 2012). Kaplan-Meier curves were constructed for the 4 comparison groups to illustrate the survival patterns during the year after treatment. Because 30-day mortality has long served as a traditional yardstick for surgical quality, 19 detailed risk analyses were determined at 30 and 365 days. Survival curves also seemed to cross over at ≈30 days.
Subgroup Analyses
In addition, CABG patients were further analyzed as 2 subgroups, those who underwent ECMO after cardiac surgery (CABG-ECMO) and those who were pretreated with ECMO before cardiac surgery (ECMO-CABG). The baseline characteristics, follow-up, and mortality patterns were reported as described above.
Results
In the period between 2002 and 2012, a total of 8329 patients were admitted to hospitals with a procedure code indicating the use of ECMO or cardiopulmonary bypass. After the exclusion of those <20 years of age, organ donors, cancer victims, and those suffering obstetric labor complications, 7266 patients remained (Figure 1 ). Among this cohort, 3944 119 Chang et al Survival of ECMO Use in Adults 2425 underwent cardiac surgical procedures, and the remaining 3322 received ECMO for other reasons. The cardiac surgery cohort included 1077 patients who were assigned to the CABG group (Figure 1) . The remaining 2867 cardiac surgical patients received only cardiopulmonary bypass during surgery and had a spectrum of procedures with insufficient numbers for further analysis ( Table I in the online-only Data Supplement). The other 3322 patients who did not receive any cardiac surgery were assigned to groups as follows: MI/CS, n=1705; injury, n=369; infection, n=1076; and others, n=172. In summary, a total of 4227 subjects were assigned to the CABG, MI/CS, injury, and infection groups for analysis (all patients in Figure 1 ). The mean±SD age of the 4227 patient cohort was 57±17 years, and 72% were male. The main diagnoses for the index hospitalizations among the 4 groups combined were acute MI (ICD-9-CM code 410.x; n=1072); other forms of chronic ischemic heart disease (ICD-9-CM code 414.x; n=439); pulmonary insufficiency after trauma and surgery (ICD-9-CM code 518.x; n=207); pneumonia, organism unspecified; heart failure; acute myocarditis; CS; cardiac arrest; influenza; and pulmonary embolism/ infarction ( Table II in the online-only Data Supplement). The patients in the 4 comparison groups differed substantially with respect to main diagnoses ( Table II in the online-only Data Supplement) and baseline characteristics ( Table 1) . The patients in the injury group were younger, had fewer comorbidities, and used fewer healthcare services before the index hospitalization. In contrast, the patients in the CABG and the MI/CS groups were more likely to have diabetes mellitus, hypertension, and cardiovascular disease with a higher Charlson Comorbidity Index. Not unexpectedly, the CABG and MI/CS groups shared a similar spectrum of atherosclerotic cardiovascular disease ( Table II in the online-only Data Supplement), differing with respect to the inclusion of CABG in the therapeutic course. Those in the infection group were more likely to have a history of chronic liver and lung disease. This chronic disease profile was associated with a greater use of medical resources as indicated by more outpatient visits, emergency room visits, and hospitalizations during the year before the index day ( Table 1 ). The most frequent complications associated with ECMO use were acute renal failure (21.3%), followed by major bleeding events (gastrointestinal bleeding, 3.1%; intracranial bleeding, 1.7%) and ischemic stroke (3.1%), among all patients. Acute renal failure was also the foremost complication in the 4 primary groups ( Table III in the online-only Data Supplement).
Patients selected for EMCO support are generally among the most seriously ill. As a result, the mean follow-up for the 4227 patients assigned to the 4 comparison groups was only 98 days. The average duration of ECMO support was 2.14 days. The overall mortality was 30.1%, 59.8%, and 76.5% at days 7, 30, and 365, respectively. The hospital discharge Table 2 . The number of days on ECMO was associated with a negative prognosis. Only a small percentage of patients used ECMO for >3 days (Figure 2A) , and positive survival outcomes became less likely as the duration of ECMO increased ( Figure 2B ). The Kaplan-Meier curves illustrates that, in the first 30 days, the patients in the infection group fared best and survival in the MI/CS group was poorest ( Figure 3A ). With MI/ CS used as the reference, the adjusted HRs and confidence limits at 1 month were 0.61 (95% CI, 0.55-0.67) for the infection group, 0.68 (95% CI, 0.61-0.75) for the CABG group, and 0.82 (95% CI, 0.70-0.95) for the injury group (Table 3) . Additional Kaplan-Meier curves were plotted for the subsequent 31-to 365-day period ( Figure 3B ) for patients who survived the first 30 days. The adjusted HRs were 0.98 (95% CI, 0.68-1.41) for the injury group, 1.31 (95% CI, 1.07-1.60) for the CABG group, and 2.00 (95% CI, 1.66-2.42) for the infection group (Table 3) for this second follow-up interval.
The subgroup analysis based on the inclusion date before and after September 1, 2009 , showed that there were no major differences in outcomes except that the death rate was lower in the infection group in the latter period (Table V in the onlineonly Data Supplement).
Discussion
This analysis of the nationwide cohort demonstrated that the hospital discharge rate was 35% and the overall 1-year survival of patients receiving ECMO was 24%. Patients with severe infection or septic shock might have better outcomes Strengths of the study arise from the large number of subjects (>4000) and decade-long duration, making it one of the largest ECMO cohorts evaluated. With the unique coding system and a linkage to the Taiwan National Death Registry, survival characteristics associated with ECMO could be ascertained. Bias associated with delays in reporting represented far less than 1% of the overall mortality in the data set analyzed. There was more than sufficient time to collect data so that the effect of any delays in reporting would have been minimal even for the last 2 years of the study period. The results of this analysis indicate that the outcomes are related to the initial indication, that is, the original cause that necessitates the life support. 22 Acute coronary syndrome complicated by shock is associated with high mortality despite the use of percutaneous support devices. 23, 24 Previously reported discharge rates in selected small case studies were ≈30 to 40%. 25, 26 In this series, coronary patients requiring ECMO had discharge rates of 35% regardless of whether CABG was performed. Despite better results in the CABG group at 30 days, both the CABG and MI/CS patients had similarly poor long-term survival rates. Patients who required ECMO before cardiac surgery (ECMO-CABG) may represent a more seriously ill population than those deemed sufficiently stable to go directly to surgery. On the other hand, those requiring postsurgical ECMO (CABG-ECMO) may represent those with the poorest postsurgical prognosis. Although the differences were not great, the discharge rate and survival statistics were better among those stable enough to elect surgery without prior ECMO support. The application of ECMO to preserve organ function when the lungs are compromised as a result of injury is a logical premise, and a few recent reports have suggested that ECMO is helpful in severely injured patients. 17 Only a few small series have argued that ECMO support could improve outcome in patients with disastrous trauma with coexisting chest injury or bleeding shock. 9, 27, 28 The preservation of major organ function by ECMO may indeed provide a better chance for survival in these patients. The present study showed a better outcome in this group of patients, especially when they survived the first month.
There are several limitations in this study. First, crucial information on vital signs and titration of inotropic agents was not available, and thus, the hemodynamic status before and after ECMO institution was unknown. The study design could classify patients only into gross categories. Second, 
Conclusions
